New heart device tested in 500 chinese patients: will it tame irregular heartbeats?

NCT ID NCT06762717

Recruiting now Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 5 times

Summary

This study tracks 500 Chinese patients with paroxysmal atrial fibrillation who are treated with the FARAPULSE pulsed field ablation system as part of their normal care. Researchers will monitor safety and effectiveness for up to three years. The goal is to see how well the device works in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FARAPULSE™ Pulsed Field Ablation system (a device that uses electrical pulses to treat irregular heartbeat)
What this could lead to: If successful, this study could confirm that the FARAPULSE system is a safe and effective option for treating atrial fibrillation in Chinese patients, potentially expanding its use.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The device is already approved, so this is about confirming real-world performance, not a breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL AF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL AF

Contacts and locations

Locations

Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China/Beijing, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.